Read-Gene S.A. (WSE:RDG)

Poland flag Poland · Delayed Price · Currency is PLN
4.700
+0.010 (0.21%)
Last updated: Jul 6, 2026, 9:00 AM CET
Market Cap55.30M +7.6%
Revenue (ttm)16.54M +33.6%
Net Income1.95M
EPSn/a
Shares Out 11.79M
PE Ratio28.36
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume50
Open4.700
Previous Close4.690
Day's Range4.700 - 4.700
52-Week Range4.520 - 6.900
Beta0.28
Analystsn/a
Price Targetn/a
Earnings DateAug 12, 2026

About Read-Gene

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. The chemoprevention segment engages in the use of natural or synthetic substances to inhibit, reverse, or delay the process of cancer. The company conducts clinical trials in cancer patients; and provides genetic tests and genetic oncology consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer. It ... [Read more]

Industry Biotechnology & Medical Research
Sector Healthcare
Founded 2005
Employees 20
Stock Exchange Warsaw Stock Exchange
Ticker Symbol RDG
Full Company Profile

Financial Performance

Financial Statements